• Dry Eye Disease impacts Visual Function

    Dry eye disease (DED) is a global, multifactorial and complex disease of the ocular surface. Currently more than 13 million Europeans and 17 million Americans are diagnosed with DED.

The majority of diagnosed DED patients fail to get a satisfactory response with current treatments. Over 60% of patients using currently approved drug therapies in the U.S. discontinue their treatment within 12 months of initiation. In particular, local intolerabilities and lack of efficacy are considered to be key reasons for the high discontinuation rates.

In addition to dryness-related symptoms, impairment of visual function plays a significant role in the reduction of work productivity and patients’ health-related quality of life. Ocular surface damage leads to on visual symptoms that affect functions such as reading, looking at screen displays, driving and night vision.

To understand DED, the underlaying causes and effects on the different physiological layers of the tear film and the ocular surface tissues have to be considered:

  • Tear film instability due to altered lipid layer

  • Tear film instability due to altered tear volume and composition

  • Meibomian gland dysfunction due to abnormal lipid secretion or obstruction

  • Mucin dysfunction due to damage

  • Epithelium dysfunction due to inflammation

  • Nerve dysfunction due to degeneration


The EyeSol® technology opens completely new and intriguing opportunities to overcome the limitations of water- or oil-based dry eye therapies.


Our products target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.